Tarsus Pharmaceuticals, Inc. (TARS) Thursday announced positive results from the Phase 2a Carpo trial evaluating TP-05 or lotilaner, an investigational oral therapeutic for the prevention of Lyme disease. TP-05 is an oral systemic formulation of lotilaner, an anti-parasitic agent.
The randomized, double-blind, placebo-controlled trial showed the ability of TP-05 to kill ticks with a single treatment evaluated compared to placebo.
In the pre-market, shares are at $33.00, up 9.53 percent from the previous close of $30.42 on a volume of 455,301.
The company said both the high and low doses of TP-05 demonstrated a statistically significant benefit in killing ticks compared to placebo. Specifically, after the Day 1 tick challenge, mean tick mortality was 97 percent compared to only 5 percent for placebo. At the 30-day challenge, mean tick mortality at 24 hours after placement was 89 percent, compared to only 9 percent for placebo.
Lyme disease is the most common vector-borne disease in the United States, transmitted to humans by Borrelia burgdorferi infection following the bite of a tick vector.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.